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Abstract
Background:  In prior work we detected reduced anti-Aβ antibody titers in Aβ-vaccinated
transgenic mice expressing the human amyloid precursor protein (APP) compared to
nontransgenic littermates. We investigated this observation further by vaccinating APP and
nontransgenic mice with either the wild-type human Aβ peptide, an Aβ peptide containing the
"Dutch Mutation", E22Q, or a wild-type Aβ peptide conjugated to papillomavirus virus-like particles
(VLPs).
Results: Anti-Aβ antibody titers were lower in vaccinated APP than nontransgenic mice even
when vaccinated with the highly immunogenic Aβ E22Q. One concern was that human Aβ derived
from the APP transgene might mask anti-Aβ antibodies in APP mice. To test this possibility, we
dissociated antigen-antibody complexes by incubation at low pH. The low pH incubation increased
the anti-Aβ antibody titers 20–40 fold in APP mice but had no effect in sera from nontransgenic
mice. However, even after dissociation, the anti-Aβ titers were still lower in transgenic mice
vaccinated with wild-type Aβ or E22Q Aβ relative to non-transgenic mice. Importantly, the
dissociated anti-Aβ titers were equivalent in nontransgenic and APP mice after VLP-based
vaccination. Control experiments demonstrated that after acid-dissociation, the increased antibody
titer did not cross react with bovine serum albumin nor alpha-synuclein, and addition of Aβ back
to the dissociated serum blocked the increase in antibody titers.
Conclusions: Circulating human Aβ can interfere with ELISA assay measurements of anti-Aβ
titers. The E22Q Aβ peptide vaccine is more immunogenic than the wild-type peptide. Unlike
peptide vaccines, VLP-based vaccines against Aβ abrogate the effects of Aβ self-tolerance.
Background
Vaccines directed against the Aβ peptide reduce amyloid
loads in amyloid precursor protein (APP) transgenic mice
[1] and protect mice from amyloid-associated memory
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impairments [2,3]. Although a fraction of patients in a
clinical Aβ vaccination trial developed adverse reactions
[4,5], there are indications that some patients benefited
from the immunization [6]. Thus, although reformula-
tion may be necessary, some form of anti-Aβ immuno-
therapy may still be a useful treatment for Alzheimer's
Disease (AD).
Several groups, including our own, have noted reduced
antibody titers in mice transgenic for human APP com-
pared to nontransgenic mice [7-9]. Typically, this was
attributed to some form of self-tolerance that could be
partially overcome with additional immunizations. One
approach to overcoming B cell tolerance to self proteins
when producing vaccines has been to conjugate the self-
antigen at high density to papillomavirus virus-like parti-
cles (VLPs; [10]). To examine whether self-tolerance plays
a role in diminishing immune responses against Aβ in
APP Tg mice, and whether VLP conjugation could over-
come tolerance, we compared the ability to induce anti-
Aβ Ig responses using wild type human Aβ peptide and
VLP conjugated Aβ. In order to detect Ab in the Tg mice,
we developed a technique to detect anti-Aβ antibodies
that are masked by circulating Aβ. In addition, we exam-
ined the immunogenicity of a human Aβ variant believed
responsible for hereditary cerebral hemorrhage with amy-
loidosis Dutch-type (DM Aβ peptide) [11], in both WT Aβ
and non-transgenic backgrounds.
Results and Discussion
Antibody responses in APP Tg mice vaccinated with WT or
VLP-conjugated Aβ were examined by ELISA using our
standard procedures [12] and anti-Aβ antibody titers were
almost undetectable using both protocols (Fig. 1, pH 7.0
results). However, nontransgenic mice did exhibit readily
measurable titers (Fig. 2, pH 7.0 results). For the DM Aβ
vaccine high anti-Aβ titers were detected in both geno-
types, albeit lower in the transgenic animals. This
prompted us to test whether circulating human Aβ might
be masking anti-Aβ antibodies in the transgenic mice.
When we compared several methods of dissociating anti-
bodies from their antigens, including dithiothreitol (100
mM), β-mercaptoethanol (0.5%) and reduced pH (pH 2.5
as described in methods), we found the acid dissociation
procedure resulted in the greatest increase in anti-Aβ anti-
body titers (4 fold greater than any of the other treat-
ments). We then tested if antigen-antibody dissociation
would increase the apparent anti-Aβ titers by comparing
incubation of the sera at pH 2.5 versus pH 7.0.
The low pH dissociation procedure caused a dramatic ele-
vation of the apparent anti-Aβ antibody titers in sera col-
lected from transgenic mice (Figure 1). The titers increased
from values near zero in the pH 7.0 incubation to roughly
8000 in the pH 2.5 incubation (t-test; P < 0.001; WT and
VLP vaccines). Samples from mice inoculated with the
DM Aβ peptide showed only a slight increase after disso-
ciation which was not statistically significant. Impor-
tantly, under all conditions, the sera from mice inoculated
with the DM peptide have substantially greater antibody
titers than mice inoculated with WT Aβ or VLP Aβ.
However, in sera from nontransgenic mice, which do not
express human Aβ, there is no effect of the acid dissocia-
tion treatment on the ELISA values (Figure 2). This indi-
cates the increase in transgenic mice is likely due to
dissociation of Aβ from the antibody in the low pH con-
dition rather than some nonspecific modification of the
antibodies caused by transient incubation at low pH. It
also implies that recovery of the antibody activity is rela-
tively intact after acid dissociation, otherwise the titers
should be reduced by the exposure to low pH in the sera
from nontransgenic mice. Again, the titers in mice vacci-
nated with the DM peptide were significantly greater than
the titers observed in mice administered the other two
vaccines (P < 0.05).
We then directly compared the anti-Aβ antibody titers in
transgenic and nontransgenic mice after acid dissociation
(Figure 3). Importantly, even after unmasking the anti-
Transgenic APP mice immunized with Aβ vaccines have  increased titers when incubated at pH 2.5 Figure 1
Transgenic APP mice immunized with Aβ vaccines have 
increased titers when incubated at pH 2.5. Results are from 
sera obtained 14 days after the fourth vaccination. Aliquots 
from each sample were incubated at either pH 2.5 or pH 7.0 
for 20 minutes, separated by centrifugation through 10,000 
MW filters and brought to neutral pH for standard ELISA 
assay. Data presented are mean ± sem. * Indicates P < 0.001 
compared to pH 7.0 (values at pH 7 are 200 and 400 for WT 
and VLP respectively). Sample size is 5–6 per group.BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/21
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bodies with the acid dissociation, the antibody titers in
transgenic mice were lower than the levels found in the
nontransgenic animals for mice administered the WT or
DM Aβ vaccines (t-test, P < 0.05). However, for mice
administered the conjugated VLP-Aβ vaccine, antibody tit-
ers were equivalent in the transgenic and nontransgenic
mice. These data argue that self-tolerance may exist in the
APP transgenic mice, and that this self-tolerance can be
overcome using the VLP-Aβ conjugated vaccine. These
results are consistent with other data using the VLP
approach to produce antibodies against self-antigens [10].
The data shown here indicate that at moderate antibody
titers, circulating human Aβ in APP transgenic mice can
interfere with the measurement of antibody titers in
standard ELISA assays. At high anti-Aβ antibody titers, as
found in the DM vaccinated mice, the antibody concen-
tration appears to exceed the Aβ concentration sufficiently
that the masking effects of Aβ have little impact on the
apparent titer in ELISA assays. In support of this
argument, we examined the effects of acid dissociation on
sera from the APP mice obtained 10 days after the second
inoculation with the DM vaccine, when titers were 1:800
without acid dissociation. In these sera, the dissociation
treatment successfully increased the anti-Aβ titers to
1:6400. Thus, the failure of acid incubation to further
increase titers for the DM peptide vaccinated mice shown
in figure 1 (after the fourth inoculation) is likely due to an
excess of antibody over circulating antigen, rather than
some alteration in the antibody or its epitope associated
with the DM vaccine. When we coated the ELISA plate
with the DM Aβ instead of the WT Aβ, we find similar tit-
ers in sera from DM vaccinated mice, implying the anti-
bodies raised with the DM vaccine are not specific to that
antigen. When antibody titers are lower, such as after just
two inoculations, acid dissociation does successfully
unmask antibody using this vaccine.
To address the issue of specificity of the Aβ values after the
acid dissociation step, we performed two control experi-
ments. In the first, we compared the ELISA signals from
antisera with and without acid dissociation after coating
the ELISA plate with alternative antigen targets in addition
to Aβ1-42 (Figure 4). These included bovine serum albu-
min, alpha-synuclein protein and Aβ11-20. While the
acid dissociation procedure slightly increased the nonspe-
cific signal found even in the absence of peptide antigens
(note the signal for PBS, phosphate buffered saline), the
large increase in signal was limited to that for the full
Nontransgenic mice immunized with Aβ vaccines do not  have increased titers when incubated at pH 2.5 Figure 2
Nontransgenic mice immunized with Aβ vaccines do not 
have increased titers when incubated at pH 2.5. Results are 
from sera obtained 14 days after the fourth vaccination. Aliq-
uots from each sample were incubated at either pH 2.5 or 
pH 7.0 for 20 minutes, separated by centrifugation through 
10,000 MW filters and brought to neutral pH for standard 
ELISA assay. Data presented are mean ± sem. Sample size is 
5–6 per group.
Comparison of anti-Aβ titers of Aβ vaccinated APP and non- transgenic mice after acid dissociation of Aβ and anti-Aβ  antibody Figure 3
Comparison of anti-Aβ titers of Aβ vaccinated APP and non-
transgenic mice after acid dissociation of Aβ and anti-Aβ 
antibody. Results are from sera obtained 14 days after the 
fourth vaccination. All samples were incubated at pH 2.5, 
centrifuged through 10,000 MW filters and neutralized 
before ELISA assay. So the effects of genotype could be 
directly compared in the three vaccine conditions, the non-
transgenic titer value for each vaccine group was set to 
100%. Data presented are mean ± sem. * P < 0.05 compared 
to APP mice given the same vaccine. Sample size is 5–6 per 
group.BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/21
Page 4 of 7
(page number not for citation purposes)
length Aβ peptide. The mid domain Aβ11-20 peptide
failed to show any antibody binding beyond that found
with PBS, consistent with the prior identification of most
anti-Aβ antibodies being directed against the N-terminal
domains [12,13].
A second experiment evaluated the ability of Aβ to com-
pete against the increased ELISA signal found after acid
dissociation. Figure 5 demonstrates that Aβ1-42 at 10–
100 µg/ml can effectively compete against the binding of
the dissociated antiserum to the ELISA plate coated with
Aβ1-42. These data suggest that the increased binding to
the ELISA plate after acid dissociation is selective for Aβ1-
42 and can be blocked by Aβ1-42 added back to the
antiserum.
Conclusions
First, circulating Aβ can interfere with anti-Aβ antibody
ELISA assays. The amount of circulating Aβ is known to
vary considerably in AD patients [13]. This observation of
antibody bound Aβ does not appear to be limited to the
Tg2576 mouse, as passive administration of anti-Aβ anti-
bodies is known to increase the amounts of Aβ in the cir-
culation of the PDAPP mouse [14] active immunization
increases circulating Aβ APP+PS1 transgenic mice [15]. It
will be important in clinical studies evaluating the circu-
lating anti-Aβ antibody content in humans to insure that
the methods used for detection are not confounded by Aβ
peptide that might be bound to these antibodies. Another
possibility is the converse; that depending upon the
methods used, circulating anti-Aβ antibodies may inter-
fere with detection of circulating Aβ. Conceivably, this
may account for the failure to observe increased Aβ after
vaccination in humans [6].
Second, the DM peptide vaccine is more effective than the
WT Aβ peptide in inducing antibody responses. Immune
responses against wild-type Aβ and the DM peptide are
reduced to a similar extent in Tg mice relative to nontrans-
genic mice, suggesting that it is unlikely that reduced self
tolerance owing to the potentially unique epitope in the
Dutch peptide sequence is responsible for the increased
immunogenicity of the DM peptide. Moreover, we found
similar titers for sera from mice vaccinated with DM Aβ
whether the ELISA was performed with the DM peptide
Specificity of increased antibody binding after acid-dissocia- tion of sera from Aβ immunized APP transgenic mice Figure 4
Specificity of increased antibody binding after acid-dissocia-
tion of sera from Aβ immunized APP transgenic mice. Sera 
were collected from transgenic mice, diluted 1:400 and pre-
incubated at either pH 7 (open bars) or pH 2.5 (solid bars) as 
described in methods. The sera were then incubated on 
ELISA plates coated with Aβ1-42, phosphate buffered saline 
(PBS; a "no protein" control), bovine serum albumin (BSA), 
recombinant alpha-synuclein (α-SYN) or Aβ peptide amino 
acids 11–20. ELISA assays were completed as described in 
Methods and the optical density at 450 nm used to estimate 
the amount of antibody binding to the ELISA plate. Results 
are presented as mean ± sem.
Competition with Aβ1-42 against the increased antibody  binding found after acid dissociation of sera from APP mice  vaccinated with Aβ Figure 5
Competition with Aβ1-42 against the increased antibody 
binding found after acid dissociation of sera from APP mice 
vaccinated with Aβ. Sera were collected from transgenic 
mice, diluted 1:1000 and preincubated at either pH 7 (open 
bars) or pH 2.5 (solid bars) as described in methods. After 
centrifugation and reconstitution of serum volume, the sera 
were incubated with Aβ1-42 at the indicated concentrations. 
Because the Aβ was initially dissolved in DMSO, some sam-
ples were also incubated with DMSO at the concentrations 
found in the 100 µg/ml Aβ incubation (2% DMSO). ELISA 
assays were completed as described in Methods and the opti-
cal density at 450 nm used to estimate the amount of anti-
body binding to the ELISA plate. Results are presented as 
mean ± sem.BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/21
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coating the plate or the WT peptide coating the plate.
However, it remains possible that T-cell help is limiting in
the induction of IgG responses to WT Aβ, and the
increased immunogenicity of the DM peptide is due to the
presence of a stronger T-cell helper epitope for this strain
of mice. Nevertheless it is interesting to note that the pri-
mary disease in patients carrying the Dutch APP mutation
is an accumulation of vascular amyloid, with few paren-
chymal deposits [11]. This is not unlike the pathology
reported in the two autopsy cases of patients vaccinated
with Aβ during a clinical trial [4,16]. In an APP mouse
model, anti-Aβ antibodies have been reported to increase
the frequency of microhemorrhage [17]. These results sug-
gest the possibility that anti-Aβ antibodies might have
some role in the unique pathology of patients carrying the
Dutch mutation.
Finally, self-tolerance to Aβ is apparent in the APP Tg
mice, and the conjugated VLP-based vaccine appears to
evade the mechanisms restricting formation of antibodies
to self antigens. As Aβ is a self-protein in AD patients, the
use of a VLP vaccine formulation may prove superior to
more traditional immunization approaches. Future stud-
ies will address the possibility that higher VLP vaccine
concentrations and/or different Aβ peptides may be even
more effective in inducing anti-Aβ antibodies in a toleriz-
ing immune background [18].
Methods
Vaccination protocols
The Tg2576 APP transgenic mice [19] and nontransgenic
littermates (produced as described in [20] were vaccinated
with human Aβ1-42 E22Q (Dutch mutant peptide; DM)
from American peptide, wild type (WT) Aβ1-42 peptide
(American peptide, Sunnyvale, CA) or papillomavirus
virus-like particles conjugated to wild type human Aβ1-40
peptide (VLP-Aβ). Peptide vaccines were prepared as
described previously [2]. Briefly, For WT and DM, Aβ pep-
tides were suspended in pyrogen-free Type I water at 2.2
mg/ml then mixed with 10 × PBS to yield 1 × PBS solution
and incubated overnight at 37 degrees C. The following
day, two volumes of 1 × PBS was added to dilute the Aβ
peptides further, and then the peptide suspension was
emulsified with an equal volume of Freund's complete
adjuvant (Sigma). The vaccine preparation (100 µg Aβ/
300  µl volume) was injected into each mouse
subcutaneously.
For the VLP material, Aβ-conjugated particles were gener-
ated by linking biotinylated Aβ peptide to biotinylated
VLPs using streptavidin. 5.6 µg biotinylated (long-chain)
Aβ1-40 peptide (AnaSpec Incorporated, San Jose, CA) was
reacted overnight at 4 degrees with 22.5 µg streptavidin
(Zymed, S. San Francisco, CA). This material was added to
7.5 µg biotinylated bovine papillomavirus (BPV) L1-VLPs
by incubation at 4 degrees overnight to generate Aβ-con-
jugated VLPs. For immunization, 130 µl complete Fre-
und's adjuvant was added to 170 µl VLP preparation
containing 5.6 µg Aβ, then emulsified and injected as 300
µl into each mouse.
For the second immunization, the same materials were
prepared freshly in incomplete Freund's adjuvant (Sigma)
at 14 days after first injection. The third and fourth boosts
were made using incomplete Freund's at monthly inter-
vals after the second immunization. Six transgenic and six
nontransgenic mice for each group were vaccinated begin-
ning at 9 months of age and sacrificed at 12 months of
age, 14 days after the fourth inoculation. Sera were col-
lected under anesthesia by retro-orbital puncture two
weeks after the second and third inoculations and by ocu-
lar enucleation at sacrifice.
Dissociation of anti-Aβ antibody from endogenous Aβ in 
serum
Sera were diluted 1:100 with dissociation buffer (PBS
buffer with 1.5% BSA and 0.2 M glycine-acetate pH 2.5),
to a 500 ul final volume and incubated for 20 min. at
room temperature (RT). The sera were then pipetted into
the sample reservoir of Microcon centrifugal filter device,
YM-10 (10,000 MW cut-off; Millipore) and centrifuged at
8,000 × g for 20 min. at RT. The sample reservoir was then
separated from the flow through, placed inverted into a
second tube and centrifuged at 1000 × g for 3 min. The
collected solution containing the antibody dissociated
from the Aβ peptide was adjusted to pH 7.0 with 15 µl of
1 M Tris buffer, pH 9.0. The retentate volume was bought
to the initial volume (500 µl) with ELISA dilution buffer
(PBS with 1.5% BSA and 0.1% Tween-20, pH 7.0). The
collected sera were then added to an ELISA plate at multi-
ple dilutions to determine the limiting antibody titer. For
non-dissociated sera values, the same serum was treated
with an identical process except using dissociation buffer
at pH 7.0 instead of dissociation buffer at pH 2.5.
Measurements of antibody titers in serum
The above dissociated sera were assayed by ELISA for anti-
body titer. Ninety-six-well Immulon 4HBX plates (Dynex)
were coated with 50 µl per well of WT Aβ1-42 peptide at
5 µg/ml in PBS buffer, pH 7.0 and incubated overnight at
4 degrees C. The plates were washed five times with 0.45%
BSA + 0.05% Tween-20 (washing buffer, WB) and blocked
at 37°C for 1 hour with blocking buffer (1.5% BSA and
0.05% Tween-20 in PBS). After five washes, the sera were
added in duplicate at an initial dilution of 1:100 and
diluted two fold serially in blocking buffer and incubated
for 1 hour at 37°C. The plates were washed 10 times and
anti-mouse IgG conjugated with horseradish peroxidase
(HRP) (Sigma Chemical Co. St. Louis, MO) diluted
1:5000 was added to the plates and incubated for 1 hourBMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/21
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at 37°C. The plates were then washed ten times and devel-
oped with 3', 3', 5', 5'-Tetramethylbenzidine (TMB;
Sigma). The reaction was stopped with 2 M sulfuric acid.
The plates were analyzed spectrophotometrically at 450
nm.
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APP: Amyloid Precursor Protein
BSA; bovine serum albumin
DM: Dutch mutation
ELISA: Enzyme linked immunosorbent assay
PBS; phosphate buffered saline
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